Interferon-Free Regimens in the Liver-Transplant Setting

被引：34

作者：

Lens, Sabela ^{[1
,2
]}

Gambato, Martina ^{[1
,2
]}

Londono, Maria-Carlota ^{[1
,2
]}

Forns, Xavier ^{[1
,2
]}

机构：

[1] IDIBAPS, Hosp Clin, Liver Unit, Barcelona, Spain

[2] CIBEREHD, Barcelona, Spain

来源：

SEMINARS IN LIVER DISEASE | 2014年 / 34卷 / 01期

关键词：

sustained virological response; liver transplantation; adverse events; direct-acting antivirals cirrhosis; HEPATITIS-C-VIRUS; SOFOSBUVIR PLUS RIBAVIRIN; HCV-INFECTED PATIENTS; SUSTAINED VIROLOGICAL RESPONSE; SINGLE-DOSE PHARMACOKINETICS; INHIBITOR-TRIPLE THERAPY; ANTIVIRAL THERAPY; GENOTYPE; INTRAVENOUS SILIBININ; FIBROSIS PROGRESSION;

D O I：

10.1055/s-0034-1371011

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

During 2014 and 2015, different interferon- (IFN-) free regimens will be approved for use in chronic hepatitis C (HCV). The liver-transplantation (LT) setting is the field of hepatology where these regimens will have the highest and fastest impact. Indeed, one study using direct-acting antivirals has already proven the concept that graft HCV infection can be prevented by treating patients awaiting LT. Safety and efficacy of several IFN-free regimens are currently being assessed in patients with hepatitis C recurrence after LT, with good preliminary results. Nevertheless, there are some issues that need to be addressed in the peri-LT setting and are reviewed in this article: (1) efficacy of IFN-free regimens in patients with advanced cirrhosis and portal hypertension, (2) pharmacokinetics of new antivirals in patients with several grades of hepatic or renal impairment, (3) impact of the selection of drug-resistant HCV strains in patients with decompensated cirrhosis or with severe hepatitis C recurrence after LT, and (4) drug-drug interactions.

引用

页码：58 / 71

页数：14

共 103 条

[1] Evolution of liver transplantation in Europe: Report of the European liver transplant registry [J].

Adam, P ;

McMaster, P ;

O'Grady, JG ;

Castaing, D ;

Klempnauer, JL ;

Jamieson, N ;

Neuhaus, P ;

Lerut, J ;

Salizzoni, M ;

Pollard, S ;

Muhlbacher, F ;

Rogiers, X ;

Valdecasas, JCG ;

Berenguer, J ;

Jaeck, D ;

Gonzalez, EM .

LIVER TRANSPLANTATION, 2003, 9 (12) :1231-1243

[2] Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection [J].

Bacon, Bruce R. ;

Gordon, Stuart C. ;

Lawitz, Eric ;

Marcellin, Patrick ;

Vierling, John M. ;

Zeuzem, Stefan ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Poordad, Fred ;

Goodman, Zachary D. ;

Sings, Heather L. ;

Boparai, Navdeep ;

Burroughs, Margaret ;

Brass, Clifford A. ;

Albrecht, Janice K. ;

Esteban, Rafael .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (13) :1207-1217

[3] Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period [J].

Barcena, Rafael ;

Moreno, Ana ;

Angel Rodriguez-Gandia, Miguel ;

Albillos, Agustin ;

Arocena, Carlos ;

Blesa, Carlos ;

Garcia-Hoz, Fernando ;

Graus, Javier ;

Nuno, Javier ;

Lopez-Hervas, Pedro ;

Gajate, Luis ;

Martinez, Adolfo ;

Bermejo, Teresa ;

Luisa Mateos, Maria ;

del Campo, Santos .

JOURNAL OF HEPATOLOGY, 2013, 58 (03) :421-426

[4] Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C [J].

Beinhardt, Sandra ;

Rasoul-Rockenschaub, Susanne ;

Scherzer, Thomas Matthias ;

Ferenci, Peter .

JOURNAL OF HEPATOLOGY, 2011, 54 (03) :591-592

[5] Liver transplantation for HCV cirrhosis:: Improved survival in recent years and increased severity of recurrent disease in female recipients:: Results of a long term retrospective study [J].

Belli, Luca S. ;

Burroughs, Andrew K. ;

Burra, Patrizia ;

Alberti, Alberto B. ;

Samonakis, Dimitrios ;

Camma, Calogero ;

De Carlis, Luciano ;

Minola, Ernesto ;

Quaglia, Alberto ;

Zavaglia, Claudio ;

Vangeli, Morcello ;

Patch, David ;

Dhillon, Amar ;

Cillo, Umberto ;

Guido, Maria ;

Fagiuoli, Stefano ;

Giacomoni, Alessandro ;

Slim, Omar A. ;

Airoldi, Aldo ;

Boninsegna, Sara ;

Davidson, Brian R. ;

Rolles, Keith ;

Pinzello, Giovambattista .

LIVER TRANSPLANTATION, 2007, 13 (05) :733-740

[6] Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation [J].

Berenguer, M. ;

Palau, A. ;

Aguilera, V. ;

Rayon, J. -M. ;

Juan, F. S. ;

Prieto, M. .

AMERICAN JOURNAL OF TRANSPLANTATION, 2008, 8 (03) :679-687

[7] HCV-related fibrosis progression following liver transplantation:: increase in recent years [J].

Berenguer, M ;

Ferrell, L ;

Watson, J ;

Prieto, M ;

Kim, M ;

Rayón, M ;

Córdoba, J ;

Herola, A ;

Ascher, N ;

Mir, J ;

Berenguer, J ;

Wright, TL .

JOURNAL OF HEPATOLOGY, 2000, 32 (04) :673-684

[8]

Bifano M, 2011, HEPATOLOGY, V54, p1004A

[9] Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation [J].

Blasco, A ;

Forns, X ;

Carrión, JA ;

García-Pagán, JC ;

Gilbert, R ;

Rimola, A ;

Nbquel, R ;

Bruguera, M ;

García-Valdecasas, JC ;

Bosch, J ;

Navasa, M .

HEPATOLOGY, 2006, 43 (03) :492-499

[10]

Brown KA, 2013, HEPATOLOGY, V58, p209A

← 1 2 3 4 5 6 7 8 9 10 →